Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
TOP STORIES — Diabetes News and Research
Ethnicity Can Affect Risk for Diabetes Complications
Letter from the Editor
If nothing else has come out of the Corona crisis, there was a lot of conversation on the repurposing of older medications to try to reduce the effects or prevent COVID-19 infection. For a while there was some “exciting” research on the use of metformin to reduce the severity. However, like a lot of medications in the end it was not the panacea that the first comments would have led us to believe.
That does not mean metformin is only good for diabetes. In an article that Abdullah Al-Ajmi, PharmD Candidate, University of Colorado School of Pharmacy, prepared for us, you can learn how metformin use in surgical patents can improve multiple outcomes.
*****************************
We can make a difference!
*****************************
Dave Joffe
Editor-in-chief
TOP STORIES — Diabetes News and Research
A diabetes patient’s risk for chronic kidney disease or cardiovascular disease can be impacted by various factors, including ethnic background.
Metformin use was associated with lower inflammatory markers before surgery, leading to improved outcomes post-surgery.
American Diabetes Association guidelines recommend that combination therapy be started in patients with unachieved glycemic control within three months.
Did You Know? Reversion from Prediabetes to Normoglycemia Reduces the Risk of CVD and Death
The current study included 14,231 participants (mean age, 58.08 years) who were free from myocardial infarction and stroke at the time of survey participation. Participants were divided into three categories according to the 2‐year changes in prediabetes mellitus, defined by fasting plasma glucose: those with progression to diabetes mellitus, those with reversion from prediabetes mellitus to normoglycemia, and those with persistent prediabetes mellitus. After a median follow‐up period of 8.75 years, a total of 879 CVD events (including 180 myocardial infarction events and 713 stroke events) and 941 all‐cause mortality events were recorded.
In this cohort study, reversion from FPG‐defined prediabetes mellitus to normoglycemia was associated with a ≈22% lower risk of a CVD event and an 18% lower risk of death than progression to diabetes mellitus. The findings from the current study extend those of previous work by demonstrating, for the first time, that reversion from prediabetes mellitus to normoglycemia is associated with a substantially lower risk for the incidence of MI and stroke than progression to diabetes mellitus. In conclusion, the current findings demonstrate the importance of reversion from prediabetes mellitus to normoglycemia in minimizing the future risk of CVD and all‐cause mortality.
Journal of the American Heart Association Jan. 26, 2021
Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this week’s newsletters:
Abdullah Al-Ajmi, PharmD Candidate, Skaggs School of Pharmacy and Pharmaceutical Sciences
Alexis Dunn, PharmD. Candidate, Florida Agricultural & Mechanical University, College of Pharmacy and Pharmaceutical Sciences
Lawand Kamal, PharmD Candidate 2021, Skaggs School of Pharmacy and Pharmaceutical Sciences
Arjay Mendoza, PharmD Candidate, University of Colorado Denver Skaggs School of Pharmacy and Pharmaceutical Sciences
Anina Pham, PharmD. Candidate, Lake Erie College of Osteopathic Medicine, College of Pharmacy
Shadrielle Robbins, PharmD Candidate, South College School of Pharmacy
Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
www.diabetesincontrol.com